PDB-code
Browse PDE entries (page 11 of 31)
First 7 8 9 PreviousLast15 14 13 Next| # | Species | PDE Type | PDB | Chain | Alternate Model | Ligand | Details | File |
|---|---|---|---|---|---|---|---|---|
 | Human | PDE2A | 4d08 | A | B | 1-(5-butoxypyridin-3-yl)-4-methyl-8-(morpholin-4-ylmethyl)[1,2,4]triazolo[4,3-a]quinoxaline |  | |
| Human | PDE2A | 4d08 | B | A | 1-(5-butoxypyridin-3-yl)-4-methyl-8-(morpholin-4-ylmethyl)[1,2,4]triazolo[4,3-a]quinoxaline | | |
| Human | PDE2A | 4d08 | B | B | 1-(5-butoxypyridin-3-yl)-4-methyl-8-(morpholin-4-ylmethyl)[1,2,4]triazolo[4,3-a]quinoxaline | | |
| Human | PDE2A | 4d08 | C | A | 1-(5-butoxypyridin-3-yl)-4-methyl-8-(morpholin-4-ylmethyl)[1,2,4]triazolo[4,3-a]quinoxaline | | |
| Human | PDE2A | 4d08 | C | B | 1-(5-butoxypyridin-3-yl)-4-methyl-8-(morpholin-4-ylmethyl)[1,2,4]triazolo[4,3-a]quinoxaline | | |
| Human | PDE2A | 4d08 | D | A | 1-(5-butoxypyridin-3-yl)-4-methyl-8-(morpholin-4-ylmethyl)[1,2,4]triazolo[4,3-a]quinoxaline | | |
| Human | PDE2A | 4d08 | D | B | 1-(5-butoxypyridin-3-yl)-4-methyl-8-(morpholin-4-ylmethyl)[1,2,4]triazolo[4,3-a]quinoxaline | | |
| Human | PDE2A | 4d09 | A | N-benzyl-4-methyl-1-phenyl[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide | | ||
| Human | PDE2A | 4d09 | B | N-benzyl-4-methyl-1-phenyl[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide | | ||
| Human | PDE2A | 4d09 | C | N-benzyl-4-methyl-1-phenyl[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide | | ||
| Human | PDE2A | 4d09 | D | N-benzyl-4-methyl-1-phenyl[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide | | ||
| Human | PDE2A | 4htx | A | A | 2-(3,4-dimethoxybenzyl)-7-[(2R,3R)-2-hydroxy-6-phenylhexan-3-yl]-5-methylimidazo[5,1-f][1,2,4]triazin-4(3H)-one | | |
| Human | PDE2A | 4htx | A | B | 2-(3,4-dimethoxybenzyl)-7-[(2R,3R)-2-hydroxy-6-phenylhexan-3-yl]-5-methylimidazo[5,1-f][1,2,4]triazin-4(3H)-one | | |
| Human | PDE2A | 4htx | B | A | 2-(3,4-dimethoxybenzyl)-7-[(2R,3R)-2-hydroxy-6-phenylhexan-3-yl]-5-methylimidazo[5,1-f][1,2,4]triazin-4(3H)-one | | |
| Human | PDE2A | 4htx | B | B | 2-(3,4-dimethoxybenzyl)-7-[(2R,3R)-2-hydroxy-6-phenylhexan-3-yl]-5-methylimidazo[5,1-f][1,2,4]triazin-4(3H)-one | | |
| Human | PDE2A | 4htx | C | A | 2-(3,4-dimethoxybenzyl)-7-[(2R,3R)-2-hydroxy-6-phenylhexan-3-yl]-5-methylimidazo[5,1-f][1,2,4]triazin-4(3H)-one | | |
| Human | PDE2A | 4htx | C | B | 2-(3,4-dimethoxybenzyl)-7-[(2R,3R)-2-hydroxy-6-phenylhexan-3-yl]-5-methylimidazo[5,1-f][1,2,4]triazin-4(3H)-one | | |
| Human | PDE2A | 4htx | D | A | 2-(3,4-dimethoxybenzyl)-7-[(2R,3R)-2-hydroxy-6-phenylhexan-3-yl]-5-methylimidazo[5,1-f][1,2,4]triazin-4(3H)-one | | |
| Human | PDE2A | 4htx | D | B | 2-(3,4-dimethoxybenzyl)-7-[(2R,3R)-2-hydroxy-6-phenylhexan-3-yl]-5-methylimidazo[5,1-f][1,2,4]triazin-4(3H)-one | | |
| Human | PDE2A | 4htz | A | A | | ||
| Human | PDE2A | 4htz | A | B | | ||
| Human | PDE2A | 4htz | B | A | | ||
| Human | PDE2A | 4htz | B | B | | ||
| Human | PDE2A | 4htz | C | A | | ||
| Human | PDE2A | 4htz | C | B | | ||
| Human | PDE2A | 4htz | D | A | | ||
| Human | PDE2A | 4htz | D | B | | ||
| Human | PDE2A | 4jib | A | A | 1-(2-hydroxyethyl)-3-(2-methylbutan-2-yl)-5-[4-(2-methyl-1H-imidazol-1-yl)phenyl]-6,7-dihydropyrazolo[4,3-e][1,4]diazepin-8(1H)-one | | |
| Human | PDE2A | 4jib | A | B | 1-(2-hydroxyethyl)-3-(2-methylbutan-2-yl)-5-[4-(2-methyl-1H-imidazol-1-yl)phenyl]-6,7-dihydropyrazolo[4,3-e][1,4]diazepin-8(1H)-one | | |
| Human | PDE2A | 4jib | A | C | 1-(2-hydroxyethyl)-3-(2-methylbutan-2-yl)-5-[4-(2-methyl-1H-imidazol-1-yl)phenyl]-6,7-dihydropyrazolo[4,3-e][1,4]diazepin-8(1H)-one | |
This research was performed as part of the "Phosphodiesterase inhibitors for neglected parasitic diseases" (PDE4NPD) programme, which is supported by the European Union 7th Framework Program (FP7/2007-2013) under grant agreement n° 602666.
